Work

626 - Lebrikizumab is an effective treatment for moderate-to-severe atopic dermatitis in patients ≥60 years of age

Year: 2024

Type: article

Source: British Journal of Dermatology

DOI: 10.1093/bjd/ljae266.010

Authors: April Armstrong, Matthew Zirwas, Maddalena Napolitano, Tiago Torres, Delphine Staumont-Salle, Amber Reck Atwater, Martin Dossenbach, Helena Agell, Sherry Chen, Meihua Qiao, Evangeline Pierce, Maria Lucia Buziqui Piruzeli, Arash Mostaghimi

Institutions: University of California, Los Angeles, Federico II University Hospital, University of Naples Federico II, Universidade do Porto, Inserm, Université de Lille, Centre Hospitalier Universitaire de Lille, Lille Inflammation Research International Center, Institute for Translational Research in Inflammation, Eli Lilly (United States), Almirall (Spain), Brigham and Women's Hospital

Language: English

Topic: Dermatology and Skin Diseases

Subfield: Dermatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4401435971

FWCI: 0.684

Cites:

Cited by: 2

Related to: 10